Keyphrases
4-cycle
50%
Adjuvant Chemotherapy
100%
Adjuvant Chemotherapy Regimens
25%
Adverse Events
25%
Breast Cancer
100%
Breast Cancer Outcomes
25%
Canadian Dollar
25%
Cancer Management
25%
Chemotherapeutic Regimens
25%
Cost-effectiveness Ratio
25%
Cost-utility
100%
Cumulative Costs
25%
Cyclophosphamide
100%
Disease-free Survival
25%
Docetaxel
100%
Doxorubicin
100%
Economic Evaluation
25%
Economic Impact
25%
Event Rate
25%
High Cost
25%
Incremental Cost
25%
Life-years Gained
50%
Literature Resources
25%
Local Resources
25%
Markov Model
25%
Model Assumptions
25%
Oncologic
25%
Oncology Trials
50%
Outcome Costs
25%
Overall Survival
25%
Payer Perspective
25%
Quality-adjusted Life Years
75%
Women with Breast Cancer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Breast Cancer
100%
Chemotherapy
100%
Chemotherapy Regimens
25%
Cyclophosphamide
100%
Disease Free Survival
25%
Docetaxel
100%
Doxorubicin
100%
Malignant Neoplasm
25%
Overall Survival
25%